The vaccine produced cross-reactive HSV-1 neutralizing antibodies and gD1 IgG binding antibodies, but low or undetectable cross-reactive binding antibodies to gC1 and gE1.<h4>Conclusions</h4>Despite occasional mild, localized breakthrough infections, the vaccine provided disease-modifying immunity and was neuroprotective. Here, EDC4 is linked to infection.